Founded in June 2002, Fangsheng Pharmaceutical is a high-quality, comprehensive, scientific research-based pharmaceutical and health industry group integrating pharmaceutical industry, medical services and big health businesses. It has many subsidiaries, December 5, 2014. It was successfully listed on the Shanghai Stock Exchange on the day and officially entered the capital market (stock code: 603998). From the establishment of the factory to the present, Fang Sheng has risen rapidly with a steady development speed and has grown into a benchmark enterprise in the pharmaceutical industry in Hunan Province.

Fang Sheng takes "Your health, Fang Sheng's pursuit" as the corporate mission. Over the past 10 years, it has been constantly exploring, trying and developing in all fields of big health, always committed to serving human health, and building a pharmaceutical industry as the The main body, with medical services and big health (health consumption, elderly care) as the strategic layout of "one body and two wings". In the pharmaceutical industry, Fangsheng Pharmaceutical Headquarters is the main body, and its subsidiary Xiangya Pharmaceuticals, Hainan Boda, Sanhua Pharmaceuticals, etc. are assisted in the joint development; at the same time, it will quickly promote the construction of Fangsheng Lip's international factory to create a way that can meet both the FDA and the NMPA. International technology platform to accelerate integration with the international market; in terms of the medical industry, relying on the two industrial funds investment targets of Baijun Medical and Kexin Health, the company's participation in investment, to meet the people's growing growth in the two major areas of kidney disease and tumors. Health service needs; in terms of healthy elderly care, using Xiangya Pharmaceutical's "Xiangya Xileyuan" as a carrier to create an elderly care life model that combines "nursing homes" and "rizhao centers" to promote the company's development layout in the elderly care industry.

Fang Sheng takes "new drug research and development capabilities" as the company's core competitive advantage, integrates the advantages of global new drug research and development resources, forms a high-level R&D team, and establishes three drugs, "Traditional medicine, chemical medicine, and biological medicine", using the imitation of complex chemical preparations, Improvement and innovation and product R&D strategies with internationalization as important characteristics have been continuously promoted to the "1+N" model of internationalized large-scale R&D system, achieving integrated development in multiple technologies and fields. In the field of traditional Chinese medicine, Fang Sheng has successfully developed several major brand series products such as Xinxuean brand cardiovascular and cerebrovascular department, Jinbeibei brand pediatrics, Meiershu brand gynecology, and Fangshengtang brand orthopedic department. In the field of chemical drugs, Fang Sheng is committed to focusing on the development of blockbuster drugs for the prevention and treatment of major diseases. The first phase I clinical trial of Deantecon sodium for injection of the Class 1 anti-cancer drug independently developed by its subsidiary Fang Sheng Huamei is about to be completed. The Phase I clinical trial of Lipo in the United States is about to be completed. Paclitaxel for injection (albumin-binding type) has completed the preliminary research and development work. In the field of biopharmaceuticals, the "National Engineering Research Center for Genetic Engineering Drugs" of Jida Genetics has successfully passed the acceptance, and its future development prospects are broad. At present, Fang Sheng has achieved the management of the entire value chain of pharmaceutical research, clinical research, consistency evaluation, production and sales in the field of new drug research and development. The company now has a nationally certified enterprise technology center and a postdoctoral research workstation. It undertakes major national new drug creation science and technology projects and a number of provincial and ministerial science and technology projects. It has obtained more than 160 drug production approval documents, nearly 20 new drug certificates, and nearly 40 invention patents. , 2 international patents, rich product reserves, provide strong support for realizing Fangsheng strategy and meeting people's health needs.

Fang Sheng has formed a professional marketing team, and the marketing network covers hospitals, chains, single pharmacies and clinics at all levels in provinces and cities across the country. With excellent product quality and professional and high-quality services, it has established the Fang Sheng brand in the field of medicine. The company fully promotes professional and academic marketing, and through diversified academic activities, we work with medical institutions at all levels to jointly improve China's overall medical level.

Fang Sheng has multiple production bases in Changsha, Hainan, Liaoning, Yunnan and other places. He organizes production strictly in accordance with the requirements of the new version of GMP and excellent performance system, establishes a complete quality control and assurance system, and implements the quality management of the entire process and all employees. Ensure the quality and safety of people's medication use. Among them, Fangsheng Pharmaceutical Industrial Park, located in Changsha Hi-tech Zone, covers an area of ​​150 mu and has a total construction area of ​​230,000 square meters, providing strong support for the company's production capacity required in its strategic development.

In the future, Fangsheng will continue to take the pharmaceutical industry as the main body, strengthen the core competitive advantages of new drug research and development, and leverage the power of capital to leverage the development of the industry, and ultimately realize the "one body and two wings" strategic layout of the pharmaceutical industry, medical services, and healthy elderly care, and create high-quality, Comprehensive and scientific research-based pharmaceutical and health industry aircraft carriers realize Fang Sheng’s dream and achieve the dream of health!